DNA vaccine of SARS-Cov S gene induces antibody response in mice
- PMID: 14732873
- PMCID: PMC7109828
- DOI: 10.1093/abbs/36.1.37
DNA vaccine of SARS-Cov S gene induces antibody response in mice
Abstract
The spike (S) protein, a main surface antigen of SARS-coronavirus (SARS-CoV), is one of the most important antigen candidates for vaccine design. In the present study, three fragments of the truncated S protein were expressed in E.coli, and analyzed with pooled sera of convalescence phase of SARS patients. The full length S gene DNA vaccine was constructed and used to immunize BALB/c mice. The mouse serum IgG antibody against SARS-CoV was measured by ELISA with E. coli expressed truncated S protein or SARS-CoV lysate as diagnostic antigen. The results showed that all the three fragments of S protein expressed by E.coli was able to react with sera of SARS patients and the S gene DNA candidate vaccine could induce the production of specific IgG antibody against SARS-CoV efficiently in mice with seroconversion ratio of 75% after 3 times of immunization. These findings lay some foundations for further understanding the immunology of SARS-CoV and developing SARS vaccines.
Similar articles
-
A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.Immunol Lett. 2008 Aug 15;119(1-2):71-7. doi: 10.1016/j.imlet.2008.04.005. Epub 2008 May 19. Immunol Lett. 2008. PMID: 18533276 Free PMC article.
-
SARS Immunity and Vaccination.Cell Mol Immunol. 2004 Jun;1(3):193-8. Cell Mol Immunol. 2004. PMID: 16219167 Review.
-
Severe acute respiratory syndrome: vaccine on the way.Chin Med J (Engl). 2005 Sep 5;118(17):1468-76. Chin Med J (Engl). 2005. PMID: 16157050 Review. No abstract available.
-
SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.Vaccine. 2005 Oct 10;23(42):4959-68. doi: 10.1016/j.vaccine.2005.05.023. Vaccine. 2005. PMID: 15993989 Free PMC article.
-
[Prokaryotic expression of SARS coronavirus spike protein and construction of its DNA vaccine].Di Yi Jun Yi Da Xue Xue Bao. 2005 Jan;25(1):33-6. Di Yi Jun Yi Da Xue Xue Bao. 2005. PMID: 15683993 Chinese.
Cited by
-
SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders.Appl Biochem Biotechnol. 2023 Feb;195(2):1541-1573. doi: 10.1007/s12010-022-04181-3. Epub 2022 Oct 12. Appl Biochem Biotechnol. 2023. PMID: 36222988 Free PMC article. Review.
-
An overview of key potential therapeutic strategies for combat in the COVID-19 battle.RSC Adv. 2020 Jul 28;10(47):28243-28266. doi: 10.1039/d0ra05434h. eCollection 2020 Jul 27. RSC Adv. 2020. PMID: 35685027 Free PMC article. Review.
-
SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines.J King Saud Univ Sci. 2021 Dec;33(8):101648. doi: 10.1016/j.jksus.2021.101648. Epub 2021 Oct 19. J King Saud Univ Sci. 2021. PMID: 34690467 Free PMC article. Review.
-
Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform.Nano Res. 2022;15(3):2196-2225. doi: 10.1007/s12274-021-3832-y. Epub 2021 Oct 9. Nano Res. 2022. PMID: 34659650 Free PMC article. Review.
-
Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.Rev Med Virol. 2021 May;31(3):e2183. doi: 10.1002/rmv.2183. Epub 2020 Oct 15. Rev Med Virol. 2021. PMID: 33594794 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous